DEZHAN HEALTHCARE(SZ:000813) Xin Lang Cai Jing·2025-10-31 23:27Company Overview - Dezheng Health was established on January 1, 1981, and listed on the Shenzhen Stock Exchange on May 19, 1998. The company is headquartered in Urumqi, Xinjiang, with its office located in Beijing. It is a leading enterprise in the research and manufacturing of cardiovascular drugs in China, with its core product being Alet (Atorvastatin Calcium Tablets), which has both brand and technological advantages [1] Financial Performance - In Q3 2025, Dezheng Health achieved a revenue of 278 million yuan, ranking 93rd among 110 companies in the industry. The top company, Huadong Medicine, reported a revenue of 32.664 billion yuan, while the second, Fosun Pharma, reported 29.393 billion yuan. The industry average revenue was 280 million yuan, with a median of 83.8 million yuan [2] - The net profit for the same period was -88.5372 million yuan, ranking 91st in the industry. The leading company, Heng Rui Medicine, reported a net profit of 5.76 billion yuan, and Fosun Pharma reported 3.056 billion yuan. The industry average net profit was 299 million yuan, with a median of 78.2908 million yuan [2] Financial Ratios - As of Q3 2025, Dezheng Health's debt-to-asset ratio was 5.18%, up from 2.63% in the same period last year, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 55.57%, down from 61.46% in the previous year, slightly below the industry average of 57.17% [3] Leadership - The controlling shareholder of Dezheng Health is Xinjiang Kaidi Investment Co., Ltd., with the actual controller being the State-owned Assets Supervision and Administration Commission of the Xinjiang Uygur Autonomous Region. The chairman, Wei Zheming, born in November 1982, holds a master's degree in business administration and has extensive management and investment experience. He has held significant positions in various companies, including Tebian Electric Apparatus and Xinjiang Lianchuang Yongjin. The general manager, Liu Wei, born in January 1970, is a licensed pharmacist with a salary of 3.98 million yuan in 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders of Dezheng Health was 57,600, a decrease of 1.13% from the previous period. The average number of circulating A-shares held per household was 36,400, down by 2.03%. Additionally, as of the same date, Hong Kong Central Clearing Limited exited the list of the top ten circulating shareholders [5]